Pruritus is a feeling stimulating the desire to scratch. Normally, Pruritus that lasts more than 6 weeks is defined as chronic itching. Chronic pruritus is a very common clinical condition that seriously affects the quality of life of people. Pruritus is associated with skin diseases, but also with a variety of systemic diseases, posing a relatively large challenge for clinical management. The incidence of chronic pruritus among adults has reached more than 10% and up to 60% among the elderly.
The activation of pruritus relies on the interaction of cells in the skin with nerve fibers, which is a process involving numerous cells, mediators and receptors, and the central transmission of pruritic signals is the final process that produces itch. The formation of chronic pruritus is associated with sensitization of neural pathways, dysregulation and altered plasticity.
Currently, there are various drugs available for the treatment of pruritus and chronic pruritus, such as antihistamines, hormones, 5-hydroxytryptamine receptor antagonists, immunosuppressants, as well as biologically targeted therapies, however, for reasons of efficacy or safety there is still a huge unmet clinical demandto develop new drugs to relieve pruritus. JAK inhibitors have demonstrated remarkable efficacy and safety in the treatment of pruritic skin diseases. The PG-011 JAK inhibitor developed by Puqi is expected to serve as a new safe and effective treatment for pruritus via its novel and well-inhibited effect on the JAK pathway.